ZGNX Zogenix, Inc.

10.35
-1.15  -10%
Previous Close 11.50
Open 11.50
Price To book 2.01
Market Cap 256.58M
Shares 24,790,000
Volume 589,449
Short Ratio 17.45
Av. Daily Volume 211,062

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 3Q 2017.
ZX008 - (Study 1502)
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved Oct 25 2013
Zohydro ER
Moderate to severe pain
Approved January 30 2015
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain
Phase 3 data due 2Q 2017.
ZX008 - Study 1501
Dravet syndrom

Latest News

  1. ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  2. Zogenix Announces CFO Transition
  3. ZOGENIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  4. Zogenix Announces CFO Transition
  5. ETFs with exposure to Zogenix, Inc. : December 21, 2016
  6. Is Foamix Pharmaceuticals Ltd (FOMX) Going to Burn These Hedge Funds?
  7. Is Zogenix Stock Still a Buy After Soaring in November?
  8. ZOGENIX, INC. Files SEC form 8-K, Other Events
  9. Zogenix Announces New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome
  10. Hedge Funds Are Piling Back Into Zogenix, Inc. (ZGNX): Should You Follow?
  11. Earnings Estimates Moving Higher for Zogenix (ZGNX): Time to Buy?
  12. Moving Average Crossover Alert: Zogenix (ZGNX)
  13. New Data on Zogenix’s ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting
  14. Zogenix to Participate in Oppenheimer Life Sciences Summit 2016
  15. Zogenix to Participate in Oppenheimer Life Sciences Summit 2016
  16. ZOGENIX, INC. Financials
  17. ETFs with exposure to Zogenix, Inc. : November 14, 2016
  18. Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
  19. Zogenix to Participate in Stifel 2016 Healthcare Conference
  20. ZOGENIX, INC. Files SEC form 10-Q, Quarterly Report

SEC Filings

  1. 8-K - Current report 17515881
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17514065
  3. 8-K - Current report 17510581
  4. 8-K - Current report 162032730
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 162002258
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979533
  7. 8-K - Current report 161978182
  8. 8-K - Current report 161971484
  9. 8-K - Current report 161903382
  10. 8-K - Current report 161854948